Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
BFRIW BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM)
0.2220.0000.00%
Close
01/31 16:00 ET
High
0.230
Open
0.230
Turnover
129.00
Low
0.222
Pre Close
0.222
Volume
573.00
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Biofrontera Inc. Announces Voting Results From 2022 Annual Meeting of Stockholders
WOBURN, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the final voting results
Biofrontera Inc. to Participate in Benchmark's 11th Annual Discovery One-on-One Investor Conference
WOBURN, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON WEDNESDAY, NOVEMBER 30, MONDAY, DECEMBER 5, FRIDAY, DECEMBER 9, AND MONDAY, DECEMBER 19 2022
Woburn, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ:BFRI), announced today that they will be participating in Renmark Financial Communications Inc.'s live
Biofrontera Reports Q3 Earnings Beat; Updates FY22 Revenue Guidance Range
Biofrontera Inc. to Report Third Quarter Financial Results on November 14, 2022
Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022
WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. ("Biofrontera" or the "Company") (NASDAQ: BFRI), announced today that they will be participating in Renmark Financial Communications
Biofrontera Inc.'s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards
Biofrontera Inc.'s Leslie Hopkins Named PM360 Trailblazer 2022 Brand Champion for Dermatology
WOBURN, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that PM360, a publication for marketing decision makers in th
Biofrontera GAAP EPS of -$0.05, revenue of $4.5M; reaffirms FY22 guidance
Biofrontera press release (NASDAQ:BFRI): Q2 GAAP EPS of -$0.05. Revenue of $4.5M (-23.7% Y/Y). As of June 30, 2022, Biofrontera Inc. had cash and cash equivalents of $31.9M, compared with $24.5M as of
Company Overview
More
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.
CEO： Ms. Erica Monaco, C.P.A.
Market： NASDAQ
Listing Date： 10/29/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet